Image-guided Biopsy Market: Investment Opportunities 2024-2032
The Image-guided Biopsy Market size was valued at USD 1.79 billion in 2023 and is expected to reach USD 3.12 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.2% over the forecast period of 2024–2031. This growth is being driven by the increasing prevalence of cancer and other chronic diseases, as well as the rising demand for minimally invasive diagnostic procedures. The image-guided biopsy market size reflects the growing importance of precision and early diagnosis in modern healthcare systems.
Technological innovations in imaging systems, such as real-time ultrasound, CT, and MRI-guided procedures, have significantly improved the accuracy and success rate of biopsies. This has made image-guided biopsy a preferred option among healthcare providers, especially in oncology. Additionally, growing awareness, improved healthcare infrastructure in emerging economies, and favorable reimbursement policies are all contributing to the market’s upward trajectory.
Get Free Sample Report @ https://www.snsinsider.com/sample-request/2859
Key Players
- Ethicon Endo-Surgery: (ENDOPOUCH Retrieval Pouch, ENDOLOOP Ligature)
- Intact Medical Corporation: (Intact Breast Lesion Excision System, Intact Excise)
- Galini SRL: (Galini Biopsy Needle, Galini Coaxial Needle)
- Hologic Inc.: (Brevera Breast Biopsy System, Eviva Breast Biopsy System)
- Leica Biosystems Nussloch GmbH: (Mammotome Elite Biopsy System, Mammotome Revolve Biopsy System)
- C. R. Bard, Inc.: (Mission Biopsy Instrument, Vacora Biopsy System)
- Becton, Dickinson and Company: (BD Vacutainer Biopsy Needle, BD Temno Biopsy Device)
- Argon Medical Devices: (SuperCore Biopsy Instrument, Tru-Core II Biopsy Needle)
- Cook Medical Incorporated: Quick-Core Biopsy Needle, EchoTip ProCore Endobronchial Ultrasound Needle)
- Encapsule Medical Devices LLC (Encapsule Biopsy System, Encapsule Core Biopsy Needle)
- Siemens Healthineers: (ACUSON S2000 Ultrasound System, Mammomat Inspiration Biopsy Unit)
- Philips Healthcare: Affiniti 70 Ultrasound System, MicroDose SI Mammography System)
- GE Healthcare: (Invenia ABUS, Senographe Pristina)
- Canon Medical Systems (Aplio i-series Ultrasound, Celesteion PET/CT System)
- Fujifilm Holdings Corporation (ARIETTA 850 Ultrasound, ASPIRE Cristalle Mammography System)
- Carestream Health: (DRX-Ascend System, DRX-Revolution Mobile X-ray System)
- Hitachi Medical Systems: (ARIETTA 70 Ultrasound, Supria CT Scanner)
- Medtronic: (O-arm Surgical Imaging System, StealthStation Surgical Navigation)
- Boston Scientific: (LithoVue Single-Use Digital Flexible Ureteroscope, SpyGlass DS Direct Visualization System)
- Stryker Corporation (NAV3i Surgical Navigation Platform, iSuite Integrated Operating Room)
Key Points:
- Market was valued at USD 1.79 billion in 2023
- Projected to grow at a CAGR of 7.2% from 2024 to 2031
- Rising demand for minimally invasive diagnostic techniques
- Increasing global incidence of cancer and chronic diseases
- Integration of real-time imaging modalities enhances diagnostic accuracy
- Emerging economies witnessing higher adoption due to improved healthcare infrastructure
- Supportive reimbursement frameworks fueling demand in developed regions
Future Scope:
The future of the image-guided biopsy market is closely tied to advancements in artificial intelligence, robotics, and machine learning, which are expected to further enhance precision and reduce human error during procedures. Expansion into untapped markets, particularly in Asia-Pacific and Latin America, offers significant growth potential. Ongoing clinical research to broaden the applications of image-guided biopsies beyond oncology, such as in cardiology and neurology, could also diversify market opportunities.
Conclusion:
As healthcare providers prioritize precision, safety, and patient comfort, the image-guided biopsy market is poised to witness steady and significant expansion in the coming years. With ongoing innovations and increasing healthcare investment worldwide, this segment is set to become an integral part of diagnostic and interventional medicine.
Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Other Related Reports:
Comments
0 comment